Tozasertib (VX-680, MK-0457)

Catalog No.S1048

Molecular Weight(MW): 464.59

Tozasertib (VX-680, MK-0457) is a pan-Aurora inhibitor, mostly against Aurora A with K_i_app of 0.6 nM in a cell-free assay, less potent towards Aurora B/Aurora C and 100-fold more selective for Aurora A than 55 other kinases. Phase 2.

Cited by 39 Publications

Nature, 2018, 559(7713):211-216

PubMed: 29973724 ( click the link to review the publication )

Cell Stem Cell, 2012, 11(2):179-94

PubMed: 22862944 ( click the link to review the publication )

Cell, 2010, 142(3):444-55

PubMed: 20691903 ( click the link to review the publication )

FEBS J, 2019, 286(5):963-974

PubMed: 30600590 ( click the link to review the publication )

Nat Chem Biol, 2016, 10.1038/nchembio.2017

PubMed: 26829474 ( click the link to review the publication )

J Biol Chem, 2016, 10.1074/jbc.M116.722751

PubMed: 27226586 ( click the link to review the publication )

Exp Cell Res, 2016, 344(2):153-66

PubMed: 27138904 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 473(1):212-8

PubMed: 27003257 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(1):31-43

PubMed: 25503564 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(23):5338-48

PubMed: 26152738 ( click the link to review the publication )

J Mol Cell Biol, 2014, 6(3):240-54

PubMed: 24847103 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1843(5):934-44

PubMed: 24480460 ( click the link to review the publication )

Hum Gene Ther, 2014, 25(7):599-608

PubMed: 24568341 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2014, 307(2):L173-85

PubMed: 24838752 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108758

PubMed: 25268132 ( click the link to review the publication )

PLoS One, 2014, 9(7):e102741

PubMed: 25048812 ( click the link to review the publication )

Oncotarget, 2014, 5(17):7498-511

PubMed: 25115395 ( click the link to review the publication )

Cancer Res, 2013, 73(22):6722-33

PubMed: 24101154 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6310-22

PubMed: 24067506 ( click the link to review the publication )

Mol Cancer Res, 2013, 12(3):433-9

PubMed: 24336958 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 5):1235-46

PubMed: 23321637 ( click the link to review the publication )

J Cell Mol Med, 2013, 17(2):265-76

PubMed: 23301855 ( click the link to review the publication )

Vet Comp Oncol, 2013, 10.1111/vco.12018

PubMed: 23410058 ( click the link to review the publication )

Eur J Cancer, 2012, 48(15):2417-30

PubMed: 22244830 ( click the link to review the publication )
Oncogene, 2012, 31(31):3584-96

PubMed: 22120720 ( click the link to review the publication )

J Med Chem, 2012, 55(17):7392-416

PubMed: 22803810 ( click the link to review the publication )

Brain Pathol, 2012, 23(3):244-53

PubMed: 22971244 ( click the link to review the publication )

J Neurosci, 2012, 32(32):11050-66

PubMed: 22875938 ( click the link to review the publication )

Biochem Pharmacol, 2012, 83(9):1217-28

PubMed: 22306067 ( click the link to review the publication )

Biochem J, 2012, 447(1):93-102

PubMed: 22784093 ( click the link to review the publication )

Exp Cell Res, 2012, 318(4):336-49

PubMed: 22197704 ( click the link to review the publication )

Cytoskeleton, 2012, 69(10):840-53

PubMed: 22887753 ( click the link to review the publication )

J Biomol Screen, 2012, 18(4):388-99

PubMed: 23134735 ( click the link to review the publication )

Pediatr Surg Int, 2012, 28(6):579-89

PubMed: 22526548 ( click the link to review the publication )

Curr Biol, 2011, 21(16):1356-65

PubMed: 21820309 ( click the link to review the publication )

Cancer Res, 2011, 71(23):7207-15

PubMed: 21978935 ( click the link to review the publication )

J Biol Chem, 2011, 286(42):36304-15

PubMed: 21878642 ( click the link to review the publication )

Biochem J, 2011, 440(1):85-93

PubMed: 21774789 ( click the link to review the publication )

Mol Cancer Ther, 2010, 9(5):1318-27

PubMed: 20388735 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Description

Targets

Aurora A ^[1] (Cell-free assay)	Aurora C ^[1] (Cell-free assay)	Aurora B ^[1] (Cell-free assay)	FLT3 ^[4] (Cell-free assay)	Bcr-Abl ^[4] (Cell-free assay)
0.6 nM(Ki app)	4.6 nM(Ki app)	18 nM(Ki app)	30 nM(Ki)	30 nM(Ki)

In vitro

Although its multi-kinase profile, VX-680 induces similar cytotoxicity with IC50 of approximately 300 nM and exhibits an AUR B-like inhibitory phenotype of G2/M arrest, endoreduplication and apoptosis in BaF3 cells transfected with ABL or FLT-3 (mutant and wild type) kinases. VX-680 prevents the CAL-62 proliferation in a time-dependent manner. VX-680 treatment for 14 days significantly decreases the number and size of colonies by approximately 70% in the 8305C and 90% in the CAL-62, 8505C and BHT-101. Treatment of the different ATC cells with VX-680 inhibits proliferation with the IC50 between 25 and 150 nM. The VX-680 significantly impairs the ability of the different cell lines to form colonies in soft agar. Analysis of caspase-3 activity indicates that VX-680 induces apoptosis in the different cell lines. CAL-62 cells exposed for 12 hours to VX-680 showed an accumulation of cells with ≥4N DNA content. Time-lapse analysis demonstrates that VX-680-treated CAL-62 cells exit metaphase without dividing. Moreover, histone H3 phosphorylation is abrogated following VX-680 treatment. ^[2] VX-680 has significant inhibitory activity against BCR-Abl bearing the T315I mutation in patient-derived samples. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
BE-13	Mn;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDMWotKSzVyPUCuNFA{OzhizszN	NXjVXlZoW0GQR2LFVi=>
RS4-11	MojoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTBwMEC0NFQh\|ryP	Mk\LV2FPT1KHUh?=
MFH-ino	NUX4[\|BVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DLRmlEPTB;MD6wNFk6KM7:TR?=	NIPwWnFUSU6JUlXS
NTERA-S-cl-D1	M1PEPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3f1PGlEPTB;MD6wNVQ{PCEQvF2=	NUnYN2Y2W0GQR2LFVi=>
697	NGDkWG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn3kTWM2OD1yLkCyOFcyKM7:TR?=	NIjRVZFUSU6JUlXS
NALM-6	MnT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLOTWM2OD1yLkCyOVUzKM7:TR?=	NH;HSZhUSU6JUlXS
ES8	MofvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPBR5hKSzVyPUCuNFQ3OTNizszN	NV7kcIR3W0GQR2LFVi=>
HUTU-80	MnLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVeydm8zUUN3ME2wMlA2Ojl7IN88US=>	NUjwSJF{W0GQR2LFVi=>
MV-4-11	M4LyWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvONVlKSzVyPUCuNFc4QDJizszN	NX23NIk1W0GQR2LFVi=>
MONO-MAC-6	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nzd2lEPTB;MD6wO\|g4QSEQvF2=	NUiyUZI3W0GQR2LFVi=>
LC-2-ad	M4HwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXvNe2xmUUN3ME2wMlA5Pzh7IN88US=>	MVfTRW5IWkWU
BL-41	NIPjWXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDiOFhjUUN3ME2wMlExPDR3IN88US=>	NFHJ[41USU6JUlXS
A4-Fuk	MonPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRTBwMUG1OlMh\|ryP	NGTXUJZUSU6JUlXS
SW954	NHHGbVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTBwMUKyNlkh\|ryP	NIO1NXRUSU6JUlXS
BV-173	Mn\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXuTWM2OD1yLkGyOlQyKM7:TR?=	MWnTRW5IWkWU
TE-11	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{jvcWlEPTB;MD6xOFk5OiEQvF2=	NHnrR5NUSU6JUlXS
SK-UT-1	NI[xWo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlzDTWM2OD1yLkG1PVY2KM7:TR?=	NVP6Z\|Q2W0GQR2LFVi=>
SIG-M5	NVP4RmhmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnS1TWM2OD1yLkG2O\|A4KM7:TR?=	Mnf4V2FPT1KHUh?=
OCUB-M	NXT3ZnNwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFf2d5VKSzVyPUCuNVY6QDNizszN	NFrZV4xUSU6JUlXS
K052	NX\uRWhNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2jtRWlEPTB;MD6xPVQ5KM7:TR?=	NV7zflM1W0GQR2LFVi=>
VA-ES-BJ	NI\YOpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWG4Soo2UUN3ME2wMlIxODh4IN88US=>	MoDGV2FPT1KHUh?=
SW982	NVP3Z5plT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnfuTWM2OD1yLkKxN\|gh\|ryP	MVHTRW5IWkWU
LB647-SCLC	NUPyblB7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1fEfGlEPTB;MD6yNVUzOyEQvF2=	Mlm1V2FPT1KHUh?=
PSN1	M3LLcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnzrTWM2OD1yLkKyNFI3KM7:TR?=	M3jBRXNCVkeURWK=
BB30-HNC	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\4fG1KSzVyPUCuNlI2QTFizszN	MkX0V2FPT1KHUh?=
ST486	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjuO\|JKSzVyPUCuNlMxQDdizszN	NWDL[VlrW0GQR2LFVi=>
MOLT-4	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTBwMkOzN\|ch\|ryP	M2\V[HNCVkeURWK=
EW-16	M2O3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlraTWM2OD1yLkKzO\|Y5KM7:TR?=	M1u0fnNCVkeURWK=
KS-1	NVrVeZB{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPBTWM2OD1yLkKzO\|g2KM7:TR?=	M4frfXNCVkeURWK=
SR	NEXsU3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX60Sno5UUN3ME2wMlI1PTZ2IN88US=>	M1HXT3NCVkeURWK=
KM12	NIrSTGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXTLNldVUUN3ME2wMlI3OzZizszN	NHLXVXRUSU6JUlXS
EM-2	M321OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHPr[XJKSzVyPUCuNlY3PDFizszN	NGnaUI1USU6JUlXS
MEG-01	MoHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTBwMke4OFkh\|ryP	MYTTRW5IWkWU
NB13	M1TOUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\ufmNCUUN3ME2wMlI4QTh2IN88US=>	MlXrV2FPT1KHUh?=
RKO	MoO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTBwM{C4NVMh\|ryP	M4TGdnNCVkeURWK=
CESS	NF21VHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3;uUGlEPTB;MD6zNVMzQCEQvF2=	NYXpdJdTW0GQR2LFVi=>
EoL-1-cell	NFmwRYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTBwM{O0OVkh\|ryP	MXLTRW5IWkWU
DOHH-2	M{jBNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\uTY5KSzVyPUCuN\|M4QDFizszN	NH\PNFFUSU6JUlXS
A388	NVTRXXhrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPnWpBKSzVyPUCuN\|QxQDZizszN	NHfUcVNUSU6JUlXS
LAMA-84	NIXXd2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NILVPVlKSzVyPUCuN\|UyPzhizszN	MVHTRW5IWkWU
IMR-5	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1:wZmlEPTB;MD6zOVU1KM7:TR?=	NUH6PFlsW0GQR2LFVi=>
KARPAS-422	NVjjVodtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHOTWM2OD1yLkO3NlczKM7:TR?=	MV;TRW5IWkWU
MRK-nu-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFXaNJJKSzVyPUCuN\|gyOyEQvF2=	M3HZRXNCVkeURWK=
BL-70	MmWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn6xTWM2OD1yLkO4PVc1KM7:TR?=	MlHWV2FPT1KHUh?=
LXF-289	M{nYPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVjIW5YzUUN3ME2wMlQxPDB4IN88US=>	NFPadVNUSU6JUlXS
RL95-2	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml7oTWM2OD1yLkSwOVY4KM7:TR?=	NUPxTpJJW0GQR2LFVi=>
QIMR-WIL	NWPHS\|ZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\FZXNnUUN3ME2wMlQzPjd4IN88US=>	M4HMR3NCVkeURWK=
K-562	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\heVFKSzVyPUCuOFM1PzJizszN	MWDTRW5IWkWU
NCI-H510A	MnrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTBwNEO4NlMh\|ryP	M2GxcHNCVkeURWK=
NCI-H524	MnTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTBwNUGxOFch\|ryP	NEHnSJZUSU6JUlXS
KE-37	NIHiRoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\vTWM2OD1yLkWyNVAzKM7:TR?=	NYrMS\|VrW0GQR2LFVi=>
KP-N-YS	NGe1S4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnLNTWM2OD1yLkW0N\|kzKM7:TR?=	NVHmfnVFW0GQR2LFVi=>
LS-411N	NWLMVIxxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3EO\|hKSzVyPUCuOVc4PTJizszN	M3TUNHNCVkeURWK=
CTV-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3ruPGlEPTB;MD61PFc4OyEQvF2=	M3\1W3NCVkeURWK=
NCI-SNU-16	M{j6Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPmTWM2OD1yLk[zOVcyKM7:TR?=	MnLNV2FPT1KHUh?=
HT-144	MlrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTBwNkO3PVgh\|ryP	Ml\4V2FPT1KHUh?=
NCI-H187	MmTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUGxemxbUUN3ME2wMlY1OTNizszN	M3;6d3NCVkeURWK=
OCI-AML2	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH36foJKSzVyPUCuOlQ1ODNizszN	MXLTRW5IWkWU
CCRF-CEM	NV73ZlJTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTBwNkWzOFYh\|ryP	NX\ZcYNQW0GQR2LFVi=>
ONS-76	M4\sN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF75UVVKSzVyPUCuOlY1PThizszN	NYewc2hQW0GQR2LFVi=>
IST-SL2	M2PKUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NID1N2tKSzVyPUCuO\|E6QDJizszN	NEXKN\|RUSU6JUlXS
NB6	M33lWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vINGlEPTB;MD63O\|I2PCEQvF2=	MnTSV2FPT1KHUh?=
SK-PN-DW	MnjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGjaUIFKSzVyPUCuO\|kyPCEQvF2=	NYHVc2tXW0GQR2LFVi=>
HCC1599	Ml\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVHiT5IyUUN3ME2wMlgxQDd2IN88US=>	MXPTRW5IWkWU
MC116	M4S0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MorYTWM2OD1yLki1NFEyKM7:TR?=	MWjTRW5IWkWU
TE-15	NGPzXYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIC0fZRKSzVyPUCuPFUxQThizszN	NEi4[VJUSU6JUlXS
HOP-62	NX3hPIY6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTBwOE[zNlkh\|ryP	NUTZdoRKW0GQR2LFVi=>
TGBC24TKB	MnXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vUdGlEPTB;MD64OlM5PSEQvF2=	NVHiTYxEW0GQR2LFVi=>
HCE-4	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4T6R2lEPTB;MD64PFA3OyEQvF2=	NH\wOoRUSU6JUlXS
ALL-PO	NUDlSIZNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;YTWM2OD1yLki4NVc2KM7:TR?=	MYDTRW5IWkWU
KGN	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4rO[WlEPTB;MD64PVk6PSEQvF2=	MoHzV2FPT1KHUh?=
ML-2	MkLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTBwOUCyOVkh\|ryP	MULTRW5IWkWU
ES4	M3PySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTBwOUGxNlgh\|ryP	MXXTRW5IWkWU
SF126	NXrNflZWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MljzTWM2OD1yLkm0PFE6KM7:TR?=	MULTRW5IWkWU
SK-N-DZ	M2KxXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1zucWlEPTB;MD65OlE5QSEQvF2=	MWrTRW5IWkWU
HCC1187	MlXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrDTWM2OD1zLkCwOVA2KM7:TR?=	MUjTRW5IWkWU
DU-4475	NH;qRphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTFwMEG3OVYh\|ryP	M2fHOnNCVkeURWK=
NKM-1	NHT2eXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUPJR\|UxRTFwMEK3O\|Uh\|ryP	NUnNeY1wW0GQR2LFVi=>
HL-60	NWTwbFF[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2PLV2lEPTB;MT6wOlU4PCEQvF2=	M{LjUHNCVkeURWK=
SBC-1	MnnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWjlTnRpUUN3ME2xMlEzPTR{IN88US=>	MUjTRW5IWkWU
TE-10	NVHWUo12T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRTFwMUK5OFYh\|ryP	NXXld3BOW0GQR2LFVi=>
ETK-1	NV3IN5BET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTFwMUO2NVMh\|ryP	NXfXU2RKW0GQR2LFVi=>
HAL-01	M4PqR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTFwMU[3NFkh\|ryP	MmC4V2FPT1KHUh?=
BB65-RCC	M{K5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jiemlEPTB;MT6xPFAxPSEQvF2=	NXHhUXhqW0GQR2LFVi=>
EW-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\WUWlEPTB;MT6xPFU3OiEQvF2=	NX2wcWhEW0GQR2LFVi=>
SK-NEP-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPJco5KSzVyPUGuNlEyOTFizszN	MYrTRW5IWkWU
SK-LMS-1	NXy4Z4o5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTFwMkKyNVIh\|ryP	MkXxV2FPT1KHUh?=
DEL	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{TTcGlEPTB;MT6yOVY1OyEQvF2=	Mnn5V2FPT1KHUh?=
GT3TKB	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPEUphjUUN3ME2xMlI5ODV5IN88US=>	MWHTRW5IWkWU
MOLT-16	MkjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm[zTWM2OD1zLkO1OFA2KM7:TR?=	NIPVOGpUSU6JUlXS
CMK	NXnCNFU6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPITWM2OD1zLkSyNVE4KM7:TR?=	NVXiRmVTW0GQR2LFVi=>
NB5	NXvuUVNXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4rqNWlEPTB;MT62OFIzQSEQvF2=	NEXsWYxUSU6JUlXS
NCI-H1963	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLOPGtVUUN3ME2xMlcxPTh\|IN88US=>	NWq0PHpvW0GQR2LFVi=>
KURAMOCHI	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWTJR\|UxRTFwN{i5NVEh\|ryP	M2XrXXNCVkeURWK=
TE-8	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYT4R2p3UUN3ME2xMlgxOzZ6IN88US=>	M{n2RnNCVkeURWK=
NCI-H1304	NHzkcGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTFwOEOwO\|Mh\|ryP	MX;TRW5IWkWU
A101D	NWj1TXVLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlTuTWM2OD1zLki3N\|k2KM7:TR?=	M33ubXNCVkeURWK=
SCLC-21H	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4S0R2lEPTB;MT65O\|A2PyEQvF2=	MVrTRW5IWkWU
GB-1	NWDZWo1UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnfDTWM2OD1{LkCxOlQ4KM7:TR?=	Mn;BV2FPT1KHUh?=
KARPAS-45	MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLrXIZ3UUN3ME2yMlAzPjV2IN88US=>	NFX2cWxUSU6JUlXS
ATN-1	NF7GeZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTJwMEK4OVgh\|ryP	MYnTRW5IWkWU
NCI-H720	NXLrU3dOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTJwME[yOFQh\|ryP	NGToe4ZUSU6JUlXS
RPMI-6666	M2LTeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7rcFdKSzVyPUKuNVYzODdizszN	MlThV2FPT1KHUh?=
NB17	NUXZWYdWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVzQe5A6UUN3ME2yMlI6OjdizszN	NUjjWXpnW0GQR2LFVi=>
IST-SL1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLTd3FEUUN3ME2yMlI6PzZ3IN88US=>	M3\OXHNCVkeURWK=
SH-4	NVHmOGVlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTJwM{K0Olkh\|ryP	Mny4V2FPT1KHUh?=
K5	M3rYO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWDuPY1VUUN3ME2yMlQxOzF7IN88US=>	NHjkdYtUSU6JUlXS
OVCAR-4	NVnibmNQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDwTWM2OD1{LkS2NVMh\|ryP	MYTTRW5IWkWU
ACN	NEHhU25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2fWUGlEPTB;Mj61NFIyOyEQvF2=	M3\0bnNCVkeURWK=
TGW	NFXmNVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3[wVmlEPTB;Mj62OVg{OiEQvF2=	Mk\TV2FPT1KHUh?=
NCI-H2107	NVXSelhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfrVJVUUUN3ME2yMlg{PzFzIN88US=>	NHXJfm5USU6JUlXS
NCI-H82	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXH4[nllUUN3ME2yMlg{QDN6IN88US=>	MUnTRW5IWkWU
SK-N-FI	M3XiRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTJwOE[4Olgh\|ryP	MYTTRW5IWkWU
LB1047-RCC	MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVH4cGZlUUN3ME2yMlg5OTJ4IN88US=>	M4r5Z3NCVkeURWK=
LU-134-A	NIDScHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmjrTWM2OD1{Lki5NlYh\|ryP	NELu[YFUSU6JUlXS
NCI-H209	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\LdFFKSzVyPUKuPVEzPTNizszN	NHvBPJZUSU6JUlXS
NOMO-1	NFHrfGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGGwXIZKSzVyPUOuNFIzPzRizszN	M33pTnNCVkeURWK=
RH-1	NEPJbWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTNwMUeyPVEh\|ryP	M2DsRnNCVkeURWK=
LOUCY	NYDvNmdCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGnsR3RKSzVyPUOuNVg3QTNizszN	MUTTRW5IWkWU
TE-9	MkTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HF[2lEPTB;Mz6yOlc{PiEQvF2=	M3voXnNCVkeURWK=
PF-382	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVjsbJBQUUN3ME2zMlM2Pzd6IN88US=>	MWjTRW5IWkWU
RPMI-8402	M2HiUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHr2SZpKSzVyPUOuOVg3ODNizszN	NITZbYFUSU6JUlXS
HEL	NEnPcnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXubY9KSzVyPUOuOlMzKM7:TR?=	NXTGUlBZW0GQR2LFVi=>
NOS-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEe1dmFKSzVyPUOuPFQ4PTRizszN	MkPvV2FPT1KHUh?=
ES1	NYS3R2VOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH\3eXZKSzVyPUOuPVIzQTNizszN	NEDZdpZUSU6JUlXS
NCI-H2171	M1:4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHHvTGlKSzVyPUOuPVI1OjNizszN	MYPTRW5IWkWU
NCI-H747	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\BbGlEPTB;Mz65OFIzOSEQvF2=	MWHTRW5IWkWU
MHH-NB-11	M{Dmfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2O1XGlEPTB;Mz65OVMyOiEQvF2=	NV71[FhrW0GQR2LFVi=>
MZ1-PC	MmTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHi0[XJKSzVyPUOuPVkzPCEQvF2=	NUX6UGJpW0GQR2LFVi=>
MMAC-SF	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlmxTWM2OD12LkCyOFY4KM7:TR?=	NUTESIFRW0GQR2LFVi=>
NMC-G1	NF7TS45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTRwMkK3NlMh\|ryP	M2jT[HNCVkeURWK=
SW872	MmTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTRwM{SzOEDPxE1?	MXXTRW5IWkWU
TE-12	Mn;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH;JVYZKSzVyPUSuOVY{QTRizszN	MVXTRW5IWkWU
LU-139	M4\ZOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTRwNkG4N\|Uh\|ryP	MYfTRW5IWkWU
HC-1	Ml;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3kXWZJUUN3ME20MlY6PDl2IN88US=>	MoD1V2FPT1KHUh?=
COR-L279	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn7HTWM2OD12Lke1PFkyKM7:TR?=	MV;TRW5IWkWU
SF268	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTRwN{m5NVYh\|ryP	M374bnNCVkeURWK=
MC-CAR	MonCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWrV[5QzUUN3ME21MlA3PzV5IN88US=>	MVrTRW5IWkWU
TK10	MlnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTVwM{W0Olkh\|ryP	M2XuVHNCVkeURWK=
TE-1	NFu2[VBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1i4T2lEPTB;NT60PVAxPCEQvF2=	MYXTRW5IWkWU
NCI-H2126	NFfBbIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfY[JFKSzVyPUWuOlQ2PzRizszN	NXrPcXo1W0GQR2LFVi=>
Daudi	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\TTWM2OD13Lk[5NVIh\|ryP	MkLuV2FPT1KHUh?=
NCI-H1648	NUmy[3dPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXqdmRKSzVyPUWuPFE1PTRizszN	MnT4V2FPT1KHUh?=
OS-RC-2	NXHFNHpjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTVwOUi1PVch\|ryP	M4rld3NCVkeURWK=
DJM-1	M1zuS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1TmPGlEPTB;Nj6zOFY3PiEQvF2=	MVjTRW5IWkWU
LS-1034	M4PjUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH:1[3BKSzVyPU[uO\|U3PiEQvF2=	MXfTRW5IWkWU
NCI-H1581	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4joSWlEPTB;Nj63PFQxPSEQvF2=	NHPTTY1USU6JUlXS
UACC-257	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\3OWdUUUN3ME23MlA1PTF{IN88US=>	NYrFV2VMW0GQR2LFVi=>
KM-H2	M3TrZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYO2[lBLUUN3ME23MlE5PDV5IN88US=>	NY\PR2NIW0GQR2LFVi=>
NCI-H1436	NVSy[m84T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTdwNkm5N\|Ih\|ryP	NVH4cmpPW0GQR2LFVi=>
IA-LM	M2TSWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXzEW4JKUUN3ME23Mlg2QSEQvF2=	NX:5OphlW0GQR2LFVi=>
NCI-H526	NHrTXFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1K1W2lEPTB;OD6yOVY{PyEQvF2=	MnXpV2FPT1KHUh?=
GCIY	M3rWUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NETZVJdKSzVyPUiuN\|Y6PjVizszN	MVjTRW5IWkWU
CP67-MEL	MnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWrTboVlUUN3ME24MlU{OjZizszN	NH:4XWhUSU6JUlXS
KALS-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{fZemlEPTB;OD64N\|g2OSEQvF2=	M1vObHNCVkeURWK=
NCI-H1770	M3f3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGO2TpdKSzVyPUiuPVAzPjVizszN	M3[5[XNCVkeURWK=
8-MG-BA	M2\P[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHyzbnZKSzVyPUmuN\|I5PDRizszN	NUXVZotoW0GQR2LFVi=>
KY821	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTlwN{e0PFQh\|ryP	MUTTRW5IWkWU
SNB75	Mn7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\oZpVKUUN3ME2xNE4xPzZizszN	NXXoVGFuW0GQR2LFVi=>
NCCIT	MmHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXve5VrUUN3ME2xNU4xPTh{IN88US=>	M3XHR3NCVkeURWK=
SJSA-1	Mnf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2r1PWlEPTB;MUGuNlg6OSEQvF2=	MVLTRW5IWkWU
LB373-MEL-D	M1HtUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTFzLkO4Nlch\|ryP	NH3VOGVUSU6JUlXS
TALL-1	M2LKT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml\jTWM2OD1zMT60NFU5KM7:TR?=	M17tc3NCVkeURWK=
NB69	M{XlW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\XfJhKSzVyPUGxMlc4ODVizszN	NIXPUJBUSU6JUlXS
NCI-H1355	NFO2NppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2[xNmlEPTB;MUGuPVQzPiEQvF2=	MXLTRW5IWkWU
DMS-153	MlzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIrRO2dKSzVyPUGyMlA1OjZizszN	MYTTRW5IWkWU
OPM-2	M2\zNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\qPVQ2UUN3ME2xNk4yPTl4IN88US=>	MWDTRW5IWkWU
NB1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWTJR\|UxRTF{LkK5JO69VQ>?	MmH2V2FPT1KHUh?=
A3-KAW	NFvwUWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWD3XWhOUUN3ME2xNk4{OjN4IN88US=>	NXXGOXVyW0GQR2LFVi=>
NCI-H1882	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPROnNvUUN3ME2xNk41ODZ4IN88US=>	MlftV2FPT1KHUh?=
KG-1	NVXGUGNHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTF{Lk[1OFUh\|ryP	MmnlV2FPT1KHUh?=
LC4-1	NEDXfGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVXnfFBPUUN3ME2xNk44PzB4IN88US=>	Ml7BV2FPT1KHUh?=
HCE-T	NETwXoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1XlcGlEPTB;MUOuNFA1QSEQvF2=	MWHTRW5IWkWU
NEC8	MoruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlnHTWM2OD1zMz6xNFM5KM7:TR?=	NVv4PXBmW0GQR2LFVi=>
IST-MEL1	M1HYTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW[2OlZVUUN3ME2xN{42Pzh6IN88US=>	M2eyPXNCVkeURWK=
EW-3	NFSwNHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LOZWlEPTB;MUOuO\|QxOiEQvF2=	NFTvToJUSU6JUlXS
CTB-1	MlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmXPTWM2OD1zND6wN\|I6KM7:TR?=	NWnY[phqW0GQR2LFVi=>
LS-123	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2DW[2lEPTB;MUSuNVU5QCEQvF2=	MVjTRW5IWkWU
NCI-H1417	M1\hbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPWZohKSzVyPUG0MlMxPTJizszN	NIO4UJRUSU6JUlXS
MZ7-mel	NVrBZnc1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnkTWM2OD1zND60OFM{KM7:TR?=	NGGzTldUSU6JUlXS
JiyoyeP-2003	MmPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDhTWM2OD1zNT62N\|I3KM7:TR?=	NHHuU5pUSU6JUlXS
ES6	NVLQOpdUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzoRZJKSzVyPUG2MlI{PjFizszN	NFfnSodUSU6JUlXS
HH	NV3RSIFwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLVZWFSUUN3ME2xO{4yQTZ\|IN88US=>	MnXpV2FPT1KHUh?=
SF539	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX;JR\|UxRTF5Lkm5NlIh\|ryP	NIrqV3JUSU6JUlXS
Calu-6	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTF7LkKzPUDPxE1?	MnjmV2FPT1KHUh?=
SK-MM-2	NYTmW\|hLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTF7LkW1OUDPxE1?	MWjTRW5IWkWU
IST-MES1	M322TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH2yXYFKSzVyPUG5MlY3PjNizszN	MVPTRW5IWkWU
GI-ME-N	MmjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTF7LkiyNlch\|ryP	MkS5V2FPT1KHUh?=
CAL-148	NWfSdGhTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1TmVGlEPTB;MkCuPVk{PCEQvF2=	MX\TRW5IWkWU
EVSA-T	MkPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTJzLkG0PVkh\|ryP	M1T6[XNCVkeURWK=
LP-1	NYGzSHpWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTJzLkO0N\|Ih\|ryP	NUfZOFBnW0GQR2LFVi=>
BOKU	MorMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M172[GlEPTB;MkGuOFU{OyEQvF2=	MWLTRW5IWkWU
KLE	NV\U[JBTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFf3bI1KSzVyPUKyMlE6ODNizszN	MkKxV2FPT1KHUh?=
LB831-BLC	MmDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTJ3LkG1NlYh\|ryP	NFH0VppUSU6JUlXS
NCI-H889	MmXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTJ3LkG5N\|Eh\|ryP	NVfOO\|B[W0GQR2LFVi=>
REH	NVOxdGRxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPjS257UUN3ME2yOU41PjdzIN88US=>	MX;TRW5IWkWU
KP-N-RT-BM-1	MmmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFnuc5pKSzVyPUK1MlQ4PTJizszN	NH;oWWhUSU6JUlXS
MPP-89	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTJ3LkWzNVQh\|ryP	MkDKV2FPT1KHUh?=
no-11	M3O5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVmx[Y1YUUN3ME2yOU44PDdizszN	NIrWWZdUSU6JUlXS
NCI-H748	MlLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\zOFhuUUN3ME2yOU44PjJ5IN88US=>	M{HndXNCVkeURWK=
LB2518-MEL	NFn6eIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG[zd4dKSzVyPUK3MlE4PzNizszN	MXHTRW5IWkWU
TGBC1TKB	M2rJZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;qXXpwUUN3ME2yO{42PTh3IN88US=>	MXPTRW5IWkWU
MHH-PREB-1	M{DCeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVf5cINLUUN3ME2yPE4xPzN2IN88US=>	MkTGV2FPT1KHUh?=
MZ2-MEL	NFi2cnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVnGfJZIUUN3ME2yPE43OTR\|IN88US=>	MlzwV2FPT1KHUh?=
U-266	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3HCdGlEPTB;MkiuOlM3PiEQvF2=	MkfpV2FPT1KHUh?=
SNU-C1	M{jwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlz5TWM2OD1{OD65OFMh\|ryP	M3zOVHNCVkeURWK=
SW962	MlztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEfldJdKSzVyPUOwMlI4PDdizszN	M1zER3NCVkeURWK=
Raji	MmHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHrte5dKSzVyPUOwMlU2QTJizszN	NYjJdGJOW0GQR2LFVi=>
KNS-42	M4ewWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn;lTWM2OD1\|MD64PVU3KM7:TR?=	MnHFV2FPT1KHUh?=
LB996-RCC	M3zOeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XUWmlEPTB;M{GuNVcxOiEQvF2=	NX;GTlRHW0GQR2LFVi=>
CHP-126	NEnydW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M130VWlEPTB;M{GuNVk5PCEQvF2=	MYPTRW5IWkWU
RXF393	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTN{LkS5O{DPxE1?	M4j1VHNCVkeURWK=
COLO-684	M1TicGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3fjeGlEPTB;M{KuOlQ{QCEQvF2=	M2XmTnNCVkeURWK=
A704	NX;JdWNrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\SUWlEPTB;M{OuOVU{QCEQvF2=	NI\tV5BUSU6JUlXS
A253	NITCXHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PTV2lEPTB;M{OuOVg2OiEQvF2=	MV7TRW5IWkWU
KNS-81-FD	M4rjZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVXSbHB4UUN3ME2zOE42PDV4IN88US=>	NEi0dINUSU6JUlXS
TE-441-T	NUexU2RuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGnzR\|RKSzVyPUO0MlY{PzFizszN	MnPhV2FPT1KHUh?=
HCC2157	NXyxZYdvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHxfFQzUUN3ME2zOU41PjF7IN88US=>	MnPxV2FPT1KHUh?=
ES3	MlyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHTRfGhKSzVyPUO2MlY4PSEQvF2=	MVHTRW5IWkWU
NCI-H1155	NVqwZlZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1nXOWlEPTB;M{euPFE2KM7:TR?=	NFTmR4lUSU6JUlXS
SNU-C2B	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn6zTWM2OD1\|OD6xOlU1KM7:TR?=	MUPTRW5IWkWU
JAR	MonUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDTTIFKSzVyPUO4MlI1PDlizszN	M4nidnNCVkeURWK=
GDM-1	MnzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUTTNolQUUN3ME2zPE46OTF4IN88US=>	NFzTZ21USU6JUlXS
KU812	M4rNb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTRzLkWwO{DPxE1?	NXfpdphqW0GQR2LFVi=>
BC-1	NU\IXFl[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEfMXGVKSzVyPUSyMlY4OzFizszN	Mli4V2FPT1KHUh?=
GI-1	NV;jdJhvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrMTWM2OD12Mj65NVkzKM7:TR?=	Ml7IV2FPT1KHUh?=
NCI-H1694	NHPzboZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRTR2Lkm0O\|Ih\|ryP	MoK4V2FPT1KHUh?=
DG-75	NF3GeJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3LFWmlEPTB;NEWuNVU4PyEQvF2=	Mm\pV2FPT1KHUh?=
COR-L88	NYTYN4R[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPUNXg5UUN3ME20OU4zPzd6IN88US=>	M4TacXNCVkeURWK=
LS-513	M3H4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\nTWM2OD12NT65NVU3KM7:TR?=	MXrTRW5IWkWU
HD-MY-Z	NX3vN21UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLabYVKSzVyPUS2MlQ3OTJizszN	M2jDe3NCVkeURWK=
L-363	NIP2SYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\TN4tKSzVyPUS2Mlg5OSEQvF2=	M{HvZ3NCVkeURWK=
TE-6	MnTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\PdI1xUUN3ME20PE41PDZizszN	Mn[1V2FPT1KHUh?=
NCI-H345	NUHLbZdMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTR6LkS2PEDPxE1?	Mn7lV2FPT1KHUh?=
TE-5	M3TFOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml\sTWM2OD12OT63NVE5KM7:TR?=	M{TybnNCVkeURWK=

... Click to View More Cell Line Experimental Data

In vivo

VX-680 gives rise to a marked decrease in tumor size in a human AML (HL-60) xenograft model. In mude mice treateed with VX-680 at 75 mg/kg, twice a day intraperitoneally (b.i.d. i.p.) for 13 days, mean tumor volumes are reduced by 98%. Tumor growth decrease is dose dependent and significant at a dose of 12.5 mg/kg b.i.d. VX-680 is well tolerated, with a small decrease in body weight observed only at the highest dose. VX-680 also triggers tumor regresson in pancreatic and colon xenograft models. VX-680 also displays potent antitumor activity when infused i.v. in mude rats bearing established HCT116 tumors. A higher dose of VX-680 (2 mg/kg/h) improves efficacy with a 56% decrease in mean tumor volume. ^[1]

Protocol

Kinase Assay: ^[3]	+ Expand Kinase inhibition assays: The consumption of ATP is coupled via the pyruvate kinase/lactic dehydrogenase enzyme pair to the oxidation of NADH, which can be monitored through the decrease in absorption at 340 nm. Reactions contains 100 mM Tris (pH 8), 10 mM MgCl₂, 2.2 mM ATP, 1 mM phosphoenolpyruvate, 0.6 mg/mL NADH, 75 units/mL pyruvate kinase, 105 units/mL lactate dehydrogenase, and 0.5 mM substrate peptide (sequence: EAIYAAPFAKKK). Reactions (75 μL) are started by adding sufficient kinase to bring the reactions to 30 nM kinase concentration and the decrease in absorbance is monitored over 30 minutes at 30°C in a microtiter plate spectrophotometer. Inhibitory constants are obtained through addition of 3.75 μL VX-680 in 100% DMSO or DMSO alone. Ki values are calculated as follows, K _i = IC50 / (1 + [S]/K_d), where [S] = [ATP] = 2.2 mM, and K_d (of ATP to Abl) = 70 μM. These values are calculated assuming a K_d (ATP) of 70 μM for wild type and H396P Abl kinase domain.
Cell Research: ^[2]	+ Expand Cell lines: CAL-62 cells Concentrations: 5-500 nM Incubation Time: 4 days Method: The CAL-62 cells are cultured in the absence (dimethyl sulfoxide, DMSO) or the presence of 500 nM VX-680 for different periods of time (1-5 days). The dose-dependent effects of VX-680 on cell proliferation are evaluated by treating the different ATC cells for 4 days with different concentrations of the Aurora inhibitor (5–500 nM). The cells are pulse labeled with 30 mM BrdU for 2 hours before the end of the incubation time. The BrdU incorporation is analyzed by means of a colorimetric immunoassay using the cell proliferation ELISA kit. The results from VX-680-treated cells are compared with those observed in control cells and expressed as a fold of variation versus control. (Only for Reference)
Animal Research: ^[1]	+ Expand Animal Models: Female athymic NCr-nu mice bearing HL-60 leukemia cells Formulation: 50% PEG300 in 50 mM phosphate buffer Dosages: 50 mg/kg, 75 mg/kg Administration: Administered via i.p. (Only for Reference)

References

[4] Cheetham GM, et al. Cancer Lett. 2007, 251(2), 323-329.

+ Expand

Solubility (25°C)

In vitro	DMSO	93 mg/mL (200.17 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+2% Tween 80+ddH2O For best results, use promptly after mixing.	15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Tozasertib (VX-680, MK-0457) SDF

Molecular Weight	464.59
Formula	C₂₃H₂₈N₈OS
CAS No.	639089-54-6
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00500006	Terminated	Chronic Myelogenous Leukemia\|Leukemia Lymphoblastic Acute Philadelphia-Positive	Merck Sharp & Dohme Corp.	October 2007	Phase 1
NCT00500006	Terminated	Chronic Myelogenous Leukemia\|Leukemia Lymphoblastic Acute Philadelphia-Positive	Merck Sharp & Dohme Corp.	October 2007	Phase 1
NCT00405054	Terminated	Leukemia	Merck Sharp & Dohme Corp.	December 2006	Phase 2
NCT00405054	Terminated	Leukemia	Merck Sharp & Dohme Corp.	December 2006	Phase 2
NCT00290550	Terminated	Carcinoma Non-Small-Cell Lung	Merck Sharp & Dohme Corp.	June 2006	Phase 2
NCT00290550	Terminated	Carcinoma Non-Small-Cell Lung	Merck Sharp & Dohme Corp.	June 2006	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Pan Aurora Kinase Inhibitors

Danusertib (PHA-739358) : Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=13 nM/79 nM/61 nM.
Pan Aurora Kinase Inhibitors

SNS-314 Mesylate : Pan-Aurora kinase inhibitor, Aurora A/B/C, IC50=9 nM/31 nM/3 nM.
Most Potent Aurora Kinase Inhibitor

MK-5108 (VX-689) : Aurora A, IC50=0.064 nM.
Aurora Kinase Inhibitor in Clinical Trial

Alisertib (MLN8237) : Phase III for Relapsed/Refractory Peripheral T-Cell Lymphoma.
Classic Aurora Kinase Inhibitor

Hesperadin : Potently inhibits Aurora B with IC50 of 250 nM.

Related Aurora Kinase Products5

Ro-3306 ^New

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases.
CCG-1423 ^New

CCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.
ML141 ^New

ML141 (CID-2950007), is demonstrated to be a potent, selective and reversible non-competitive inhibitor of Cdc42 GTPase suitable for in vitro assays, with IC50 of 200 nM and selectivity against other members of the Rho family of GTPases (Rac1, Rab2, Rab7).
Alisertib (MLN8237)

Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.

Features:First orally available inhibitor of Aurora A.
Barasertib (AZD1152-HQPA|AZD2811)

Barasertib (AZD1152-HQPA) is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay, ~3700 fold more selective for Aurora B over Aurora A. Phase 1.
Danusertib (PHA-739358)

Danusertib (PHA-739358) is an Aurora kinase inhibitor for Aurora A/B/C with IC50 of 13 nM/79 nM/61 nM in cell-free assays, modestly potent to Abl, TrkA, c-RET and FGFR1, and less potent to Lck, VEGFR2/3, c-Kit, CDK2, etc. Phase 2.
ZM 447439

ZM 447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM and 130 nM, respectively. It is more than 8-fold selective for Aurora A/B than MEK1, Src, Lck and has little effect against CDK1/2/4, Plk1, Chk1, etc.

Features:An Aurora selective ATP-competitive inhibitor.
MLN8054

MLN8054 is a potent and selective inhibitor of Aurora A with IC50 of 4 nM in Sf9 insect cell. It is more than 40-fold selective for Aurora A than Aurora B. Phase 1.
MK-5108 (VX-689)

MK-5108 (VX-689) is a highly selective Aurora A inhibitor with IC50 of 0.064 nM in a cell-free assay and is 220- and 190-fold more selective for Aurora A than Aurora B/C, while it inhibits TrkA with less than 100-fold selectivity. Phase 1.
Aurora A Inhibitor I (TC-S 7010)

Aurora A Inhibitor I is a novel, potent, and selective inhibitor of Aurora A with IC50 of 3.4 nM in a cell-free assay. It is 1000-fold more selective for Aurora A than Aurora B.

Features:Aurora A Inhibitor I is a novel, potent, and selective inhibitor to Aurora A.

Choose Your Country or Region

By Signaling Pathways

By product type

Tozasertib (VX-680, MK-0457)

Cited by 39 Publications

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Tozasertib (VX-680, MK-0457) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Related Aurora Kinase Products5

Choose Your Country or Region

By Signaling Pathways

By product type

Tozasertib (VX-680, MK-0457)

Cited by 39 Publications

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Tozasertib (VX-680, MK-0457) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Related Aurora Kinase Products5

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)